Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion
Review of the available RCT evidence (8 RCTs; n=1631) suggests that treatment of macular oedema, secondary to branch retinal vein occlusion, with anti‐VEGF (ranibizumab, aflibercept, bevacizumab) improves visual and anatomical outcomes at 6 and 12 months.
Source:
Cochrane Database of Systematic Reviews